Abstract
Patients with cancer and cancer survivors are vulnerable to infection, rendering vaccination a necessary intervention. The vaccination process represents a unique challenge in these populations-it is often impossible or impractical to delay the start of cancer treatment for immunizations, and vaccines may fail to trigger an appropriate protective immune response in immunocompromised patients and cancer survivors, with residual immune deficits. Additionally, live attenuated vaccines are contraindicated due to an increased risk of prolonged shedding and disease presence. The current NCCN Guidelines for Survivorship, which reflect the most up-to-date, evidence-based data relating to survivorship, detail the appropriate immunization practices in these highly susceptible populations.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 607-610 |
| Number of pages | 4 |
| Journal | JNCCN Journal of the National Comprehensive Cancer Network |
| Volume | 20 |
| Issue number | 5.5 |
| DOIs | |
| State | Published - Jun 2022 |
ASJC Scopus subject areas
- Oncology
Fingerprint
Dive into the research topics of 'Vaccinations for Patients With Cancer and Cancer Survivors'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS